Sun Pharmaceutical Industries Ltd (SUN.NS)

SUN.NS on National Stock Exchange of India

782.20INR
25 Jul 2014
Price Change (% chg)

Rs34.00 (+4.54%)
Prev Close
Rs748.20
Open
Rs750.05
Day's High
Rs785.00
Day's Low
Rs750.05
Volume
2,015,432
Avg. Vol
2,331,873
52-wk High
Rs785.00
52-wk Low
Rs475.35

SUN.NS

Chart for SUN.NS

About

Sun Pharmaceutical Industries Limited is an international specialty pharma company. The Company manufactures and markets pharmaceutical formulations as branded generics, as well as generics in India, the United states and several other markets across the world. The Company’s business is divided into four segments: US Generics,... (more)

Overall

Beta: 0.66
Market Cap (Mil.): Rs1,549,645.00
Shares Outstanding (Mil.): 2,071.16
Dividend: 2.50
Yield (%): 0.33

Financials

  SUN.NS Industry Sector
P/E (TTM): 48.22 35.80 36.21
EPS (TTM): 15.52 -- --
ROI: 20.83 18.99 18.26
ROE: 18.97 19.76 19.13
Search Stocks

Sun Pharma acquires U.S.-based Pharmalucence

MUMBAI - Sun Pharmaceutical Industries Ltd , India's third-largest generic drugmaker by sales, said on Wednesday it had acquired U.S.-based Pharmalucence Inc, which has sterile injectable capacity and research capabilities.

16 Jul 2014

India's Sun Pharma acquires U.S.-based Pharmalucence

MUMBAI, July 16 - Sun Pharmaceutical Industries Ltd, India's third-largest generic drugmaker by sales, said on Wednesday it had acquired U.S.-based Pharmalucence Inc, which has sterile injectable capacity and research capabilities.

16 Jul 2014

BSE Sensex edges higher; defensive stocks surge

MUMBAI - The BSE Sensex and Nifty rose on Friday as defensive stocks such as Sun Pharmaceutical Industries and Ranbaxy Laboratories jumped on the U.S. regulator's approval for a key drug while IT stocks gained after rival Accenture Plc reported robust quarterly revenue growth.

27 Jun 2014

Indian shares edge higher; defensives surge

* BSE index gains 0.15 pct; NSE ends 0.21 pct higher * Century Textile rallies after investor Damani buys stake * Aban likely to launch up to $150 mln share sale on Friday - sources * Ranbaxy gets FDA approval for Novartis's Diovan generic By Abhishek Vishnoi MUMBAI, June 27 - Indian shares rose on Friday as defensive stocks such as Sun Pharmaceutical Industries and Ranbaxy Laboratories jumped on the U.S. regulator's approval for a key drug while IT stocks gained

27 Jun 2014

Indian shares edge higher; defensive stocks surge

MUMBAI, June 27 - Indian shares rose on Friday as defensive stocks such as Sun Pharmaceutical Industries and Ranbaxy Laboratories jumped on the U.S. regulator's approval for a key drug while IT stocks gained after rival Accenture Plc reported robust quarterly revenue growth.

27 Jun 2014

MARKET EYE-Indian shares edge higher; Ranbaxy, Sun gain

* India's benchmark BSE index gains 0.36 percent, while the broader NSE index is up 0.39 percent. * Gains were led by value-buying in blue-chip stocks such as Oil and Natural Gas Corp after the stock fell sharply in the previous session. ONGC gains 1.2 percent after falling 5.8 percent on Thursday. * Shares in Ranbaxy Laboratories Ltd are up 4.7 percent and Sun Pharmaceuticals Industries Ltd gains 3.65 percent after the U.S. Food and Drug Administration approved the company's generic version of

27 Jun 2014

Sun Pharma response to import ban inadequate - FDA

REUTERS - Generic drugmaker Sun Pharmaceutical Industries Ltd's response to an import ban on one of its plants lacked "sufficient corrective actions," the U.S. Food and Drug Administration said in a warning letter published on Tuesday.

20 May 2014

Ranbaxy posts loss after write-offs on U.S. import bans

MUMBAI - Drugmaker Ranbaxy Laboratories Ltd , which has agreed to be acquired by Sun Pharmaceutical Industries Ltd for $3.2 billion, posted a loss in the March quarter, hit by write-offs related to regulatory sanctions.

09 May 2014

UPDATE 1-India's Ranbaxy posts loss after write-offs on US import bans

* Compares with analysts' forecast for 958.7 mln in profit

09 May 2014

India's Ranbaxy posts March-quarter loss on write-offs

MUMBAI, May 9 - Indian drugmaker Ranbaxy Laboratories Ltd, which has agreed to be acquired by rival Sun Pharmaceutical Industries Ltd for $3.2 billion, posted a surprise loss in the March quarter due to write-offs related to regulatory sanctions for poor manufacturing quality.

09 May 2014

Earnings vs. Estimates

Search Stocks